Author name: DrugPatentWatch

1. The Structural Re-Alignment of the Pharmaceutical Value Chain The pharmaceutical industry is currently undergoing a structural metamorphosis as significant […]

Introduction: The Two Engines of Pharma Value – Clinical Success and IP Fortresses In the high-stakes world of biopharmaceutical investment,

Introduction: The Billion-Dollar Question – Decoding the Link Between Patents and Market Value In the intricate and high-stakes world of

Introduction: Beyond the Crystal Ball—Forecasting as a Strategic Weapon Biopharmaceutical innovation operates under the shadow of “Eroom’s Law”—Moore’s Law spelled

Introduction: Beyond Purchase Price – Redefining Value in Pharma Procurement In the intricate and high-stakes world of pharmaceutical procurement, the

Litigation Summary and Analysis for Bristol-Myers Squibb Company v. Azurity Pharmaceuticals, Inc. | 1:25-cv-01558 Executive Summary This litigation revolves around

Part I: The Hatch-Waxman Gauntlet: Foundational Principles and Economic Stakes 1.1 The Grand Compromise: Deconstructing the Hatch-Waxman Act The modern

I. Introduction: A Precarious Symbiosis The United States healthcare landscape is shaped by a complex web of federal statutes, each

Introduction: The End of an Era and the Dawn of a New Playbook The generic pharmaceutical industry operates at the